Le Petit Livre du Cannabis Médical Nicolas Authier, Editions First, 2021, 149 pages Sommaire Petit livre Cannabis Médical - N Authier
Lire la suiteMedical use of cannabis products. Lessons to be learned from Israel and Canada J. Ablin, P.A. Ste-Marie, M. Schäfer, W. Häuser, M.-A. Fitzcharles Der Schmerz, 2016, 1-10 DOI 10.1007/s00482-015-0083-4 © Deutsche Schmerzgesellschaft e.V. Published by Springer-Verlag Berlin Heidelberg - all rights reserved 2015 Abstract Introduction : The German government intends to reduce the barriers for the medical use of cannabis products. A discussion on the indications and contraindications of the medical use of cannabis and on the changes of the regulatory framework has already begun in Germany. It is useful to draw from the experiences of other countries with a more liberal medical use of cannabis. Methods [...]
Lire la suiteThe pharmacokinetics and the pharmacodynamics of cannabinoids Catherine J. Lucas, Peter Galettis and Jennifer Schneider British Journal of Clinical Pharmacology, 2018, 84, 2477–2482 DOI:10.1111/bcp.13710 Abstract : There is increasing interest in the use of cannabinoids for disease and symptom management, but limited information available regarding their pharmacokinetics and pharmacodynamics to guide prescribers. Cannabis medicines contain a wide variety of chemical compounds, including the cannabinoids delta-9-tetrahydrocannabinol (THC), which is psychoactive, and the nonpsychoactive cannabidiol (CBD). Cannabis use is associated with both pathological and behavioural toxicity and, accordingly, is contraindicated in the context of significant psychiatric, cardiovascular, renal or hepatic illness. The pharmacokinetics of cannabinoids and the [...]
Lire la suite